logo
episode-header-image
Nov 2022
32m 41s

Why Don’t We Have a Cure for Alzheimer’s...

Freakonomics Radio + Stitcher
About this episode

Promising drugs keep failing in trials. Allegations of fraud have cast a shadow over the field. An expert explains why Alzheimer’s treatments have been so hard to find — and why one clue may lie in the Andes Mountains.

Up next
Jul 2023
The Economics of Everyday Things: Animal Urine
In the newest show from the Freakonomics Radio Network, host Zachary Crockett explores the hidden side of the things around us. This week: One creature’s trash is another’s cash. (Or, how one man found profit in pee.) 
12m 57s
Jul 2023
Tom Brady, A.D.H.D., and a Really Bad Headache (Bonus)
A sneak peek at Bapu's new book, Random Acts of Medicine, available now from Doubleday, and an announcement about the show. 
37m 40s
Mar 2023
78. Do Kids Cause Divorce?
Couples get divorced for all kinds of reasons. Is having kids one of them? Bapu talks about research that investigates what happens to parents who unexpectedly have twins. Plus, an announcement about the future of the show. 
18m 50s
Recommended Episodes
Sep 2021
What Causes Alzheimer's?
The human brain is mysterious and complicated. So much so, one might be tempted to argue that it only makes sense that we still don’t have a cure for Alzheimer’s disease, despite decades of research. But this isn’t the whole story. We’ve partnered with Vox’s Unexplainable science ... Show More
29m 54s
Mar 2023
How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
A new drug for Alzheimer's disease, called lecanemab, got a lot of attention earlier this year for getting fast-tracked approval based on a clinical trial that included nearly 1,800 people. It was the most diverse trial for an Alzheimer's treatment to date, but still not enough t ... Show More
13m 46s
Aug 2021
Controversial new Alzheimer's drug in the spotlight
After decades without progress, this June a new treatment was approved by the US Food and Drugs Administration - Biogen's Aduhelm. Ivana Davidovic looks into why this process has been so controversial that is now under investigation by a federal watchdog.Aaron Kesselheim, a Harva ... Show More
18m 21s
Jun 2021
Alzheimer’s drug has experts divided; rising ICE use in Australia; the disappointing results of a study aimed at improving ovarian cancer survival rates
This week, the first of a new series on substance use and what you need to know about ICE - crystal meth. Does early diagnosis of ovarian cancer through screening make a difference to survival rates? And the search for an Alzheimer's disease treatment is as controversial as ever. ... Show More
35m 10s
Feb 2021
What you can do to prevent Alzheimer's | Lisa Genova
Alzheimer's doesn't have to be your brain's destiny, says neuroscientist and author of "Still Alice," Lisa Genova. She shares the latest science investigating the disease -- and some promising research on what each of us can do to build an Alzheimer's-resistant brain. Hosted on A ... Show More
14m 6s
May 2015
Funding World Class Dementia Research
An overview on Dementia and why Alzheimers Research UK is here 
11m 29s
Nov 2021
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ... Show More
9m 45s
Jul 2023
How close are we to ending Alzheimer's?
A new drug, Donanemab, has been hailed as a turning point in the fight against Alzheimer's after a global trial confirms it slows cognitive decline.One trial was shown to have “significantly slowed” the progression of the disease—by 35%.Earlier this year, Lecanemab, the first dru ... Show More
48m 39s
Jun 2021
FDA Approves Aducanumab — A Controversial Drug For Alzheimer's
The FDA has approved a new drug for Alzheimer's. But a lot of experts are skeptical about whether the drug works. Rhitu Chatterjee talks with science correspondent Jon Hamilton about the controversial drug aducanumab and why the U.S. Food and Drug Administration approved it. For ... Show More
11m 52s
Aug 2021
Alzheimer’s Dementia
Alzheimer’s disease is a devastating neurodegenerative condition that affects the entire family. As psychiatrists and psychologists, we often support these patients and their families throughout this entire disease process. With the recent and controversial FDA approval of aducan ... Show More
57m 32s